Skip to content

Common Stock at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$292M0.0%
AbbVie logo
AbbVieABBV
$18M0.0%
Immunome logo
ImmunomeIMNM
$11K+22.2%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$9K0.0%
Incyte logo
IncyteINCY
400M0.0%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
390M+30.0%

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Market cap$3.54B+226%
Enterprise value$3.46B+275%
P/S15×+7.3×

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's common stock?
Arcus Biosciences (RCUS) reported common stock of 400M in Q1 2026.
How has Arcus Biosciences's common stock changed year-over-year?
Arcus Biosciences's common stock decreased by 0.0% year-over-year, from 400M to 400M.
What is the long-term trend for Arcus Biosciences's common stock?
Over 5 years (2020 to 2025), Arcus Biosciences's common stock has grown at a 822.1% compound annual growth rate (CAGR), from 6K to 400M.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).